AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19321313 — intervention group
Group type: COMPARATOR
Intervention: Traditional psychiatric care (control group)
Number of subjects: 54
Study 19321313 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem enhancement program (overall satisfaction)
Number of subjects: 54
Study 17299581 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaseolus vulgaris extract (445 mg) taken one tablet per day for 30 days before a carbohydrate-rich meal
Number of subjects: 60
Study 17299581 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken one tablet per day for 30 days before a carbohydrate-rich meal
Number of subjects: 60
Study 15117912 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 2579
Study 11606175 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1250 mg) and Vitamin E (680 IU) per day
Number of subjects: 30
Study 11606175 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30
Study 9540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole/amoxicillin for 2 weeks
Number of subjects: 233
Study 9540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole for 2 weeks
Number of subjects: 233
Study 9540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 2 weeks
Number of subjects: 233
Study 9540877 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole for an additional 2 weeks (study 1)
Number of subjects: 233
Study 9540877 — intervention group
Group type: COMPARATOR
Intervention: Placebo for an additional 2 weeks (study 1)
Number of subjects: 233
Study 8031487 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage device
Number of subjects: 20
Study 8031487 — intervention group
Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 20
Study 3836875 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 19
Study 29658756 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 346
Study 29658756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 346
Study 27935990 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibition (2x40mg parecoxib on day of surgery, thereafter 2x200mg celecoxib/day until day five)
Number of subjects: 138
Study 27935990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 27935990 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibition
Number of subjects: 138
Study 27935990 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persistent pain (VAS>30 at 12 months)
Number of subjects: 138
Study 23461899 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 161
Study 23461899 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 161
Study 23461899 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 161
Study 22607100 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 14
Study 22607100 — intervention group
Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 14
Study 20557237 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-artesunate (30 mg/kg per day of azithromycin plus 4 mg/kg per day of artesunate) once daily for 3 days
Number of subjects: 228
Study 20557237 — intervention group
Group type: COMPARATOR
Intervention: Control: Artemether (80 mg) plus Lumefantrine (960 mg) twice daily for 3 days
Number of subjects: 228
Study 20557237 — intervention group
Group type: COMPARATOR
Intervention: Control: Artemether plus Lumefantrine
Number of subjects: 228
Study 18534016 — intervention group
Group type: EXPERIMENTAL
Intervention: ACZ885 10 mg/kg
Number of subjects: 32
Study 18534016 — intervention group
Group type: EXPERIMENTAL
Intervention: ACZ885
Number of subjects: 32
Study 18534016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18991519 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment (twice-weekly for 8 weeks)
Number of subjects: 100
Study 18991519 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch treatment (twice-weekly for 8 weeks)
Number of subjects: 100
Study 18991519 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant therapy (twice-weekly for 8 weeks)
Number of subjects: 100
Study 18991519 — intervention group
Group type: COMPARATOR
Intervention: Sham control (twice-weekly for 8 weeks)
Number of subjects: 100
Study 15149781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa‐HBV‐IPV/Hib vaccine (Infanrix hexa)
Number of subjects: 2163
Study 15149781 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTPa‐IPV/Hib and HBV vaccines
Number of subjects: 2163
Study 11054323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (oral administration)
Number of subjects: 21
Study 9352390 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (180 mg diltiazem-HCl)
Number of subjects: 20
Study 1378786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gallopamil 0.03 mg/kg
Number of subjects: 12
Study 1378786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3516406 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 27
Study 3516406 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen
Number of subjects: 27
Study 31567658 — intervention group
Group type: EXPERIMENTAL
Intervention: BearStand behavioral intervention group
Number of subjects: 52
Study 29540123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate combined with oral nimodipine
Number of subjects: 120
Study 29540123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26285807 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic antibiotics
Number of subjects: 100
Study 26285807 — intervention group
Group type: EXPERIMENTAL
Intervention: Local use of chlorhexidine
Number of subjects: 100
Study 26285807 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy without adjunctive treatment
Number of subjects: 100
Study 25388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 90 Hz for 20 minutes daily for 12 months
Number of subjects: 202
Study 25388526 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 30 Hz for 20 minutes daily for 12 months
Number of subjects: 202
Study 25388526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WBV)
Number of subjects: 202
Study 21827635 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion during exercise
Number of subjects: 0
Study 21827635 — intervention group
Group type: COMPARATOR
Intervention: Saline (control, CON) infusion during exercise
Number of subjects: 0
Study 19212238 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Lok (LL) implant
Number of subjects: 15
Study 19212238 — intervention group
Group type: COMPARATOR
Intervention: Control implant
Number of subjects: 15
Study 17513982 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 184
Study 17513982 — intervention group
Group type: EXPERIMENTAL
Intervention: MetadateCD/Equasym XL
Number of subjects: 184
Study 17513982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 15292287 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional morning dose of hydrocortisone
Number of subjects: 9
Study 15292287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11420801 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led AIDS education
Number of subjects: 0
Study 10193287 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (10, 20, 30 and 40%)
Number of subjects: 12
Study 10193287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (15, 30, 45 and 60%)
Number of subjects: 12
Study 8164045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg isotretinoin daily for 6 months
Number of subjects: 86
Study 8164045 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 86
Study 3284481 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case surgery
Number of subjects: 70
Study 3284481 — intervention group
Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 70
Study 29127533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab 2 mg/kg
Number of subjects: 76
Study 29127533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab 4 mg/kg
Number of subjects: 76
Study 29127533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab (both doses)
Number of subjects: 76
Study 29127533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 76
Study 27605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 27605392 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM (active metabolite of Ticagrelor)
Number of subjects: 0
Study 27605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 27605392 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS2211 (P2Y13 antagonist)
Number of subjects: 0
Study 27605392 — intervention group
Group type: EXPERIMENTAL
Intervention: TIM (inactive metabolite of Ticagrelor)
Number of subjects: 0
Study 27605392 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor (in PLATO trial)
Number of subjects: 0
Study 24091567 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 10344
Study 24091567 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted risk index
Number of subjects: 10344
Study 24091567 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical population
Number of subjects: 10344
Study 24360173 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow gastric tube (NGT)
Number of subjects: 104
Study 24360173 — intervention group
Group type: COMPARATOR
Intervention: Whole stomach (WS)
Number of subjects: 104
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA₂DS₂‐VASc scheme
Number of subjects: 7329
Study 20966417 — intervention group
Group type: COMPARATOR
Intervention: NICE 2006
Number of subjects: 7329
Study 20966417 — intervention group
Group type: COMPARATOR
Intervention: Other contemporary RSS
Number of subjects: 7329
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA₂DS₂‐VASc score
Number of subjects: 7329
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 75 years or older
Number of subjects: 7329
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 7329
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 7329
Study 20966417 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported alcohol use
Number of subjects: 7329
Study 19058662 — intervention group
Group type: EXPERIMENTAL
Intervention: T-shirt odors rated by women
Number of subjects: 44
Study 19058662 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial photographs rated by women
Number of subjects: 44
Study 16791444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard balanced anesthesia in morbidly obese patients
Number of subjects: 60
Study 16791444 — intervention group
Group type: COMPARATOR
Intervention: Standard balanced anesthesia in nonobese patients
Number of subjects: 60
Study 16791444 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hemodynamic measurements during surgery
Number of subjects: 60
Study 16791444 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodes of hemodynamic instability
Number of subjects: 60
Study 12442345 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 or 10 mg)
Number of subjects: 24
Study 12442345 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 24
Study 9989712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.4 mg/kg bolus then 0.15 mg kg(‐1) h(‐1) infusion; n=5083)
Number of subjects: 10141
Study 9989712 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 units bolus then 15 units kg(‐1) h(‐1); n=5058)
Number of subjects: 10141
Study 9989712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141
Study 9989712 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 10141
Study 8524697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (G)
Number of subjects: 26
Study 8524697 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (M)
Number of subjects: 26
Study 2156976 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans Administration (VA) Medical Center
Number of subjects: 45
Study 2156976 — intervention group
Group type: COMPARATOR
Intervention: Private hospital
Number of subjects: 45
Study 2156976 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental Rating Scale
Number of subjects: 45
Study 6933739 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestasert
Number of subjects: 0
Study 6933739 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0
Study 31715077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily (n = 30)
Number of subjects: 62
Study 31715077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 62
Study 31715077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 62
Study 31715077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31216327 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest report (computer task measuring attention, impulsivity and activity)
Number of subjects: 250
Study 31216327 — intervention group
Group type: COMPARATOR
Intervention: No QbTest report
Number of subjects: 250
Study 27899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided crosslinking (PiXL)
Number of subjects: 37
Study 27899371 — intervention group
Group type: COMPARATOR
Intervention: Uniform 9 mm crosslinking (CXL)
Number of subjects: 37
Study 27899371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 37
Study 25929531 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement System Impairment (MSI)-based classification treatment
Number of subjects: 148
Study 25929531 — intervention group
Group type: COMPARATOR
Intervention: General exercise program (stretching and strengthening exercises)
Number of subjects: 148
Study 23709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA)
Number of subjects: 69
Study 23709314 — intervention group
Group type: COMPARATOR
Intervention: Assessment As Usual (AAU)
Number of subjects: 69
Study 21233774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR)
Number of subjects: 14
Study 21233774 — intervention group
Group type: COMPARATOR
Intervention: Fluid Intake (FI)
Number of subjects: 14
Study 21233774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 14
Study 21233774 — intervention group
Group type: EXPERIMENTAL
Intervention: TearLab osmolarity system
Number of subjects: 14
Study 21233774 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Specific Gravity (USG)
Number of subjects: 14
Study 19179203 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 375
Study 19179203 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril/indapamide
Number of subjects: 375
Study 17251530 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 600
Study 17251530 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 600
Study 14732637 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-plane face-lift
Number of subjects: 40
Study 14732637 — intervention group
Group type: COMPARATOR
Intervention: SMAS plication face-lift
Number of subjects: 40
Study 11757831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin ointment
Number of subjects: 14
Study 11757831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampin
Number of subjects: 14
Study 11757831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin or mupirocin
Number of subjects: 14
Study 11757831 — intervention group
Group type: COMPARATOR
Intervention: Oral rifampin prophylaxis
Number of subjects: 14
Study 11757831 — intervention group
Group type: COMPARATOR
Intervention: Nasal or exit-site mupirocin
Number of subjects: 14
Study 9299803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 28
Study 9299803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8401551 — intervention group
Group type: EXPERIMENTAL
Intervention: High calorie preload
Number of subjects: 0
Study 8401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report rating scales
Number of subjects: 0
Study 8401551 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop task
Number of subjects: 0
Study 3717693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 1 unit of blood @ 5 ml/min
Number of subjects: 40
Study 3717693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 2 units of blood @ 10 ml/min
Number of subjects: 40
Study 3717693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 2 units of blood @ 5 ml/min
Number of subjects: 40
Study 3717693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 1 unit of blood @ 10 ml/min
Number of subjects: 40
Study 31188229 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.1%
Number of subjects: 68
Study 31188229 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 68
Study 28918703 — intervention group
Group type: EXPERIMENTAL
Intervention: RPH+sMMH
Number of subjects: 3000
Study 28918703 — intervention group
Group type: EXPERIMENTAL
Intervention: RPH alone
Number of subjects: 3000
Study 28918703 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (MMH, PPH, PPH+sMMH)
Number of subjects: 3000
Study 25963295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture with Neiguan (PC6)
Number of subjects: 0
Study 25963295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture with Zhongwan (CV12)
Number of subjects: 0
Study 25963295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture with both PC6 and CV12
Number of subjects: 0
Study 25963295 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic only (Control)
Number of subjects: 0
Study 25963295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (all groups)
Number of subjects: 0
Study 23231499 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg of misoprostol orally
Number of subjects: 99
Study 23231499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 21796123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (standard-dose candesartan 8 mg/day + controlled-release nifedipine 20 mg/day)
Number of subjects: 86
Study 21796123 — intervention group
Group type: COMPARATOR
Intervention: Up-titrated monotherapy (candesartan 12 mg/day)
Number of subjects: 86
Study 19182483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 103
Study 19182483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 16981108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose 50 %
Number of subjects: 50
Study 16981108 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 15342168 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation within 30 days
Number of subjects: 7800
Study 15342168 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 7800
Study 11025708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy (150 mg daily)
Number of subjects: 480
Study 11025708 — intervention group
Group type: COMPARATOR
Intervention: Castration (orchiectomy or 3.6 mg goserelin acetate every 28 days)
Number of subjects: 480
Study 9195140 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual assessment and treatment provided in a stroke unit
Number of subjects: 0
Study 9195140 — intervention group
Group type: COMPARATOR
Intervention: Conventional wards (control)
Number of subjects: 0
Study 9195140 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual impairment assessment using Rey figure copy
Number of subjects: 0
Study 8257455 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg daily
Number of subjects: 20
Study 8257455 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3086203 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin alone (0.66 units per min)
Number of subjects: 39
Study 3086203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin plus sublingual nitroglycerin (0.6 mg every 30 min for 6 hr)
Number of subjects: 39
Study 3296856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 92
Study 3296856 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 92
Study 31381021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 febrile UTI
Number of subjects: 345
Study 31381021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 febrile UTIs
Number of subjects: 345
Study 31381021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or more febrile UTIs
Number of subjects: 345
Study 28560853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (gefitinib combined with pemetrexed and carboplatin)
Number of subjects: 121
Study 28560853 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed plus carboplatin)
Number of subjects: 121
Study 28560853 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 121
Study 25041275 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.33, 0.34, 0.38 U/kg)
Number of subjects: 62
Study 23877013 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of cytotoxic treatment (≤ 28 days)
Number of subjects: 191
Study 23877013 — intervention group
Group type: COMPARATOR
Intervention: Timing of cytotoxic treatment (> 28 days)
Number of subjects: 191
Study 23877013 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative residual disease (n=70)
Number of subjects: 191